Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer

Sponsor
Yue Gou
Study ID
NCT06849362
Status
Enrolling By Invitation

Conditions

  • Immunotherapy
  • MSS Metastatic Colorectal Cancer
  • Metastatic Colorectal Cancer (CRC)

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody used in combination with chemotherapy or immunotherapy for the treatment of metastatic colorectal cancer (CRC). In this study, bevacizumab is administered as part of combination therapy in certain patient groups to assess its impact on treatment efficacy in MSS/MSI-L/pMMR advanced colorectal cancer. Patients receiving bevacizumab will be evaluated for treatment response, survival outcomes, and potential biomarkers predictive of therapeutic efficacy. The study will compare the clinical benefits of immunotherapy alone, immunotherapy + bevacizumab, and immunotherapy + chemotherapy + bevacizumab to determine the optimal treatment strategy. The dose and administration schedule of bevacizumab will follow standard clinical guidelines as per institutional protocols.

Study Details

This multicenter retrospective study aims to evaluate and optimize combination immunotherapy strategies for patients with microsatellite stable (MSS), microsatellite instability-low (MSI-L), or mismatch repair-proficient (pMMR) advanced colorectal cancer (CRC). The study will analyze clinical outcomes, treatment responses, and prognostic factors in patients who received various immunotherapy regimens. Data from multiple institutions will be collected to identify potential predictive biomarkers and effective therapeutic combinations. The findings may provide critical insights for improving immunotherapy strategies in MSS/MSI-L/pMMR CRC patients.

Key Dates

First listed
Feb 27, 2025
Start date
Dec 1, 2019
Status verified
Feb 2025
Primary completion
Feb 28, 2024
Completion
May 30, 2025

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Immunotherapy + Bevacizumab Group
    Immunotherapy + Bevacizumab Group
  • Arm: Immunotherapy only Group
    Immunotherapy only
  • Arm: Immunotherapy + Chemotherapy + Bevacizumab Group
    Immunotherapy + Chemotherapy + Bevacizumab
  • Arm: Chemotherapy only Group
    Chemotherapy only

Primary Outcome Measure

Disease Control Rate [ Time Frame: 02/28/2024 ]

Related Studies